TKI agents reduce the incidence of brain mets in RCC

[Olga]

Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
http://www.ncbi.nlm.nih.gov/pubmed/21484781
the full text is avail. free online here:
http://onlinelibrary.wiley.com/doi/10.1 ... 26138/full
The conclusion:
Treatment with TKI agents reduces the incidence of brain metastasis in mRCC.
TKI agents that are currently in use (approved for RCC and other cancers but can be used in ASPS off label if the oncologist finds it appropriate) - sunitinib, sorafenib, pazopanib plus there is a clinical trial for cediranib at the NCI.